PD-L1、p53、C-myc在弥漫性大B细胞性淋巴瘤中的表达及意义  

Significance of PD-L1,p53 and C-myc protein expression in diffuse large B-cell lymphoma

作　　者：吴晨阳 王潇飞 张爽 罗丹 董丽儒 宋旭东 WU Chen-yang;WANG Xiao-fei;ZHANG Shuang;LUO Dan;DONG Li-ru;SONG Xu-dong(Department of Pathology,Affiliated Hospital of North China University of Science and Technology,Tangshan 063000,China)

机构地区：[1]华北理工大学附属医院病理科,河北唐山063000

出　　处：《诊断病理学杂志》2020年第6期408-412,共5页Chinese Journal of Diagnostic Pathology

摘　　要：目的探讨程序性死亡配体-1(PD-L1)、p53、C-myc蛋白在弥漫性大B细胞性淋巴瘤(DLBCL)中的表达及其与临床病理特征的关系。方法采用免疫组化法检测50例DLBCL组织中的PD-L1、p53及C-myc蛋白的表达,分析其与临床病理特征的关系,同时对C-myc阳性病例进一步行FISH检测筛查高级别B细胞性淋巴瘤(HGBL)。结果50例DLBCL中瘤细胞PD-L1、p53、C-myc阳性率分别为42%(21/50)、18%(9/50)、14%(7/50),PD-L1的表达与Hans分型有关(P<0.05),而与患者性别、年龄、发病部位、Ki-67指数、Ann Arbor分期、国际预后指数(IPI)评分、血清乳酸脱氢酶(LDH)水平、ECOG评分及有/无B症状无关(P>0.05);p53、C-myc表达与DLBCL的临床病理特征之间均不具有相关性(P>0.05)。FISH检测结果未出现高级别B细胞性淋巴瘤。结论PD-L1在DLBCL中高表达,且在非生发中心B细胞样(non-GCB)亚型中有更高的阳性率,可为临床应用抗PD-L1免疫抑制剂行免疫治疗提供理论依据。Objective To explore the expression and clinical significance of programmed death-ligand 1(PD-L1),p53 and C-myc in diffuse large B-cell lymphoma(DLBCL).Methods Immunohistochemistry(IHC)En Vision was used to detect the expression of PD-L1,p53 and C-myc in 50 cases of DLBCL.FISH analysis was used to detect c-myc genetic alteration in c-myc protein positive cases of high-grade B-cell lymphoma(HGBL).Results The positive rates of PD-L1,p53 and C-myc in 50 cases of DLBCL were 42%(21/50),18%(9/50)and 14%(7/50).The expression levels of PD-L1 was significantly associated with immunohistochemical Hans typing(P<0.05),but age,sex,primary site,Ki-67 index,Ann Arbor stage,the international standardization of prognostic index(IPI),serum lactate dehydrogenase(LDH),ECOG grade and B symptom had no significant correlation(P>0.05).There were no correlation between the expression of p53,C-myc protein and the clinicopathological features of DLBCL(P>0.05).No c-myc gene arrangement in high-grade B-cell lymphoma was found by FISH.Conclusions PD-L1 is highly expressed in DLBCL and has the higher positive rate in non-GCB type,which provides a theoretical basis for the clinical application of anti-PD-L1 immunosuppressive agents in immunotherapy.

关 键 词：弥漫性大B细胞性淋巴瘤 程序性死亡配体-1 P53 C-MYC 免疫组化 

分 类 号：T733.1[一般工业技术]